The FONICAP group is screening, with randomised phase II studies, the activity of new chemotherapy programmes for advanced non-small-cell lung cancer (NSCLC) looking for regimens with > 30\% activity. In the present study, three regimens were tested: MIP (mitomycin 6 mg m-2, ifosfamide 3 g m-2, cisplatinum 80 mg m-2 on day 1 every 28 days); MIP-IFN (MIP and interferon alpha-2b 3 MU s.c. three times a week); and PC (cisplatinum 60 mg m-2 and carboplatin 400 mg m-2 on day 1 every 28 days). Overall 93 chemotherapy-naive patients were enrolled: 23 received MIP, 27 received MIP-IFN and 43 received PC. Eighty per cent of the patients had stage IV and 20\% stage IIIb disease (positive pleural effusion or supraclavicular nodes). Response rates were as follows: MIP = 9\% (95\% CI 1-28\%), MIP-IFN = 7\% (95\% CI 1-24\%) and PC = 14\% (95\% CI 5-28\%). The overall median survival was 183 days. Grade III-IV leucopenia was observed in 36\% of patients treated with MIP-IFN vs 10\% in the other two arms, and thrombocytopenia grade III-IV was reported in nearly 10\% of patients overall. In conclusion, (1) all three regimens investigated have poor activity (< 30\%); (2) when tested in multicentre randomised phase II trials, MIP displays lower activity than in phase II trials; (3) PC has similar activity to other platinum-containing regimens; (4) randomised phase II studies are a reliable and quick method of determining the anti-tumour activity of novel chemotherapeutic regimens in NSCLC.

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force / A., Ardizzoni; G. F., Addamo; E., Baldini; U., Borghini; L., Portalone; F. D., Marinis; R., Lionetto; Conte, Pierfranco; P., Bruzzi; M. C., Pennucci. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 71:(1995), pp. 115-119.

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.

CONTE, Pierfranco;
1995

Abstract

The FONICAP group is screening, with randomised phase II studies, the activity of new chemotherapy programmes for advanced non-small-cell lung cancer (NSCLC) looking for regimens with > 30\% activity. In the present study, three regimens were tested: MIP (mitomycin 6 mg m-2, ifosfamide 3 g m-2, cisplatinum 80 mg m-2 on day 1 every 28 days); MIP-IFN (MIP and interferon alpha-2b 3 MU s.c. three times a week); and PC (cisplatinum 60 mg m-2 and carboplatin 400 mg m-2 on day 1 every 28 days). Overall 93 chemotherapy-naive patients were enrolled: 23 received MIP, 27 received MIP-IFN and 43 received PC. Eighty per cent of the patients had stage IV and 20\% stage IIIb disease (positive pleural effusion or supraclavicular nodes). Response rates were as follows: MIP = 9\% (95\% CI 1-28\%), MIP-IFN = 7\% (95\% CI 1-24\%) and PC = 14\% (95\% CI 5-28\%). The overall median survival was 183 days. Grade III-IV leucopenia was observed in 36\% of patients treated with MIP-IFN vs 10\% in the other two arms, and thrombocytopenia grade III-IV was reported in nearly 10\% of patients overall. In conclusion, (1) all three regimens investigated have poor activity (< 30\%); (2) when tested in multicentre randomised phase II trials, MIP displays lower activity than in phase II trials; (3) PC has similar activity to other platinum-containing regimens; (4) randomised phase II studies are a reliable and quick method of determining the anti-tumour activity of novel chemotherapeutic regimens in NSCLC.
1995
71
115
119
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force / A., Ardizzoni; G. F., Addamo; E., Baldini; U., Borghini; L., Portalone; F. D., Marinis; R., Lionetto; Conte, Pierfranco; P., Bruzzi; M. C., Pennucci. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 71:(1995), pp. 115-119.
A., Ardizzoni; G. F., Addamo; E., Baldini; U., Borghini; L., Portalone; F. D., Marinis; R., Lionetto; Conte, Pierfranco; P., Bruzzi; M. C., Pennucci
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/739442
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact